Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications

Trial Profile

Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Branch retinal vein occlusion; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms OCEAN
  • Sponsors Novartis
  • Most Recent Events

    • 28 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 27 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top